Substance / Medication

Cholic acid

Overview

Active Ingredient
cholic acid
RxNorm CUI
1440856
Labeler: Mirum Pharmaceuticals Inc.Updated: 2026-01-26T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Abreu Eliabe S, Fernandes Gabriel Prusch, Lacerda Henrique de Carvalho et al. · J Gastroenterol Hepatol · 2025
PMID: 41025397Meta-Analysis
Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Abreu Eliabe S, Reginato Pedro Henrique, Pitanga Jorge Ferreira Jasmineiro et al. · Dig Dis Sci · 2025
PMID: 40253557Meta-Analysis
The effects of ursodeoxycholic acid on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials.
Rashidbeygi Elaheh, Rasaei Niloufar, Amini Mohammad Reza et al. · BMC Cardiovasc Disord · 2025
PMID: 39984850Meta-AnalysisFull text (PMC)
MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
Wang Hanxiao, Li You, Pu Xiting et al. · J Gastroenterol · 2024
PMID: 37845416Meta-Analysis
The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review.
Polak Yasmin, van Dussen Laura, Kemper E Marleen et al. · Orphanet J Rare Dis · 2024
PMID: 39702264Meta-AnalysisFull text (PMC)
Ursodeoxycholic acid for preventing parenteral nutrition-associated cholestasis in neonates: A systematic review and meta-analysis.
Anne Rajendra Prasad, Kadyada Srikanth Puttaiah, Aradhya Abhishek Somasekhara et al. · Fundam Clin Pharmacol · 2024
PMID: 38342497Meta-Analysis
Role of Obeticholic Acid, a Farnesoid X Receptor Agonist, in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
Kamrul-Hasan Abm, Mondal Sunetra, Nagendra Lakshmi et al. · touchREV Endocrinol · 2024
PMID: 39526049Meta-AnalysisFull text (PMC)
Neuroprotective Effect of Tauroursodeoxycholic Acid (TUDCA) onandModels of Retinal Disorders: A Systematic Review.
Li Jiaxian, Huang Ziyang, Jin Yu et al. · Curr Neuropharmacol · 2024
PMID: 37691227Meta-AnalysisFull text (PMC)
Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo Nidah Shabbir, Sultan Shahnaz, Reynolds John M et al. · Dig Dis Sci · 2023
PMID: 36180756Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cholic acid (substance)
SNOMED CT
17147002
UMLS CUI
C0055568
RxNorm CUI
1440856
Labeler
Mirum Pharmaceuticals Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.